| Filed On | Filing |
|---|---|
| 12 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 424B3 |
| 04 Nov 2026 | 424B3 |
| 03 Nov 2026 |
Form 4: Tamboli Ajim, Chief Financial Officer
Granted 42,500 Common Stock |
| 03 Nov 2026 |
Form 4: Faga Daniel, Director
Granted 136,000 Common Stock |
| 03 Nov 2026 |
Form 4: Stone Benjamin, Chief Business Officer
Granted 42,500 Common Stock |
| 03 Nov 2026 |
Form 4: Lizzul Paul F., Chief Medical Officer
Granted 42,500 Common Stock |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD) |
| 29 Oct 2026 | EFFECT |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 26 Oct 2026 | S-1 |
| 20 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 19, 2026, is entered into by and among First Tracks Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (ind... |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SECURITIES PURCHASE AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 19... |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms |
| 17 Sep 2026 |
Form 4: Orwin John A, Director
Received 1,300 shares by exercise or conversion |
| 04 Sep 2026 |
Form 4: Ware J. Anthony, Director
Received 39,265 shares by exercise or conversion ($225K) · Sold 39,265 shares ($1.76M) |
| 02 Sep 2026 | 144 |
| 18 Aug 2026 |
Form 4: Stone Benjamin, Chief Business Officer
Granted 60,492 Performance Stock Units |
Loading...